Tag Archives: malignant peritoneal mesothelioma.

Protein Marker Linked to Prognosis in Peritoneal Mesothelioma

A cellular marker that helps tell cancer cells to replicate may be used to predict treatment outcomes in people with malignant peritoneal mesothelioma. That conclusion comes from a group of researchers at Australia’s University of New South Wales. The researchers tested tissue samples from 42 mesothelioma patients for the presence of Ki67, a protein associated with cell proliferation. According to the authors, Ki67 has been widely used as a prognostic indicator in other types of cancer, but has not been tested in mesothelioma. The researchers divided the tissue samples into two groups based on their level of Ki67 expression. Those with a Ki67 expression of less than 25% were put in the low category and all samples above that were … Continue reading Protein Marker Linked to Prognosis in Peritoneal Mesothelioma »

Tracking Mesothelioma with FDG-PET

The imaging method called positron emission tomography (PET) using the radioactive tracer molecule 18F-FDG is a valuable way to both diagnose and track the progression of malignant peritoneal mesothelioma. Nuclear medicine researchers at a Hospital in Barcelona, Spain reviewed the diagnostic and treatment records of 60 people with malignant peritoneal mesothelioma, a form of mesothelioma that spreads on the membrane lining the walls of the abdomen. The study subjects included 34 women and 26 men with a mean age of 53. All the patients in the study had had multiple 18-F-FDG-PET scans to diagnose or track their cancer. Eleven of the studied patients had an FDG-PET scan prior to receiving treatment. In all cases, the scans showed characteristic mesothelioma disease … Continue reading Tracking Mesothelioma with FDG-PET »

New Serum Marker Could Improve Mesothelioma Diagnosis

serum

Japanese researchers believe they have found a way to diagnose a rare form of mesothelioma earlier using a simple blood test. Diffuse malignant peritoneal mesothelioma (DMPM), which represents about a fourth of all mesothelioma cases, is an aggressive malignancy that spreads across the lining of the abdomen. In most cases, DMPM is lethal within a year. The standard treatment for diffuse malignant peritoneal mesothelioma is cytoreductive surgery to remove as much of the mesothelioma as possible, followed by intraperitoneal chemotherapy to destroy residual cancer cells. In some studies, this approach has resulted in 5-year survival rates of 30 to 60 percent. However, it is most successful when it is performed early, while the primary mesothelioma tumor is more easily removed. Like all forms of … Continue reading New Serum Marker Could Improve Mesothelioma Diagnosis »

Estrogen May Impact Mesothelioma Prognosis

hormone

Researchers in New South Wales, Australia may have found one of the reasons for survival differences in men and women with malignant peritoneal mesothelioma. The key may be in their hormones. The sex hormone estradiol is produced by the ovaries and the adrenal gland in women and is an active metabolic product of testosterone (though in much lower levels) in men. The most important form of estrogen in the body, estradiol has been shown to be involved in cellular proliferation of a number of cancers and acts mainly through estrogen receptors. Peritoneal mesothelioma is a cancer than spreads across the thin membrane that lines the wall of the abdomen. Using immunohistochemical testing, the Australian team measured estrogen receptors in 42 patients … Continue reading Estrogen May Impact Mesothelioma Prognosis »